I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Samit Hirawat Biography and Net Worth

EVP, Chief Medical Officer and Head of Development of Bristol-Myers Squibb

Samit Hirawat, MD, executive vice president, chief medical officer and head of Development, oversees early-stage and late-stage product development across all therapeutic areas. In this role, Samit and his organization focus on enabling the rapid progression and delivery of assets, from proof-of-concept to commercialization, through world-class clinical trial design and operations.

Samit joined Bristol Myers Squibb in 2019 with extensive drug development experience, most recently serving as executive vice president and head of Oncology Development for Novartis. Previously, he led clinical development programs in multiple indications at PTC Therapeutics and Pfizer/Pharmacia Corporation.

Samit earned his bachelor of medicine, bachelor of surgery (MBBS) at Sawai Man Singh Medical College in India, and completed his internal medicine residency and medical oncology training at North Shore University Hospital, New York.

What is Samit Hirawat's net worth?: The estimated net worth of Samit Hirawat is at least $3.56 million as of November 1st, 2024. Dr. Hirawat owns 62,109 shares of Bristol-Myers Squibb stock worth more than $3,560,709 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Hirawat may own. Additionally, Dr. Hirawat receives a salary of $2,620,000.00 as EVP, Chief Medical Officer and Head of Development at Bristol-Myers Squibb. Learn More about Samit Hirawat's net worth.
How old is Samit Hirawat?: Dr. Hirawat is currently 55 years old. There are 7 older executives and no younger executives at Bristol-Myers Squibb. The oldest executive at Bristol-Myers Squibb is Dr. Joseph J. Eiden Jr., Head of Medical Affairs, who is 75 years old. Learn More on Samit Hirawat's age.
What is Samit Hirawat's salary?: As the EVP, Chief Medical Officer and Head of Development of Bristol-Myers Squibb, Dr. Hirawat earns $2,620,000.00 per year. The highest earning executive at Bristol-Myers Squibb is Dr. Christopher S. Boerner Ph.D., CEO & Chairman, who commands a salary of $3,140,000.00 per year. Learn More on Samit Hirawat's salary.
How do I contact Samit Hirawat?: The corporate mailing address for Dr. Hirawat and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Samit Hirawat's contact information.
Has Samit Hirawat been buying or selling shares of Bristol-Myers Squibb?: Within the last three months, Samit Hirawat has bought $100,046.10 of Bristol-Myers Squibb stock. Most recently, on Friday, November 1st, Samit Hirawat bought 1,830 shares of Bristol-Myers Squibb stock. The stock was acquired at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the transaction, the executive vice president now directly owns 62,109 shares of the company's stock, valued at $3,395,499.03. Learn More on Samit Hirawat's trading history.
Who are Bristol-Myers Squibb's active insiders?: Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Samit Hirawat (EVP, Chief Medical Officer and Head of Development), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?: During the last year, Bristol-Myers Squibb insiders bought shares 1 times. They purchased a total of 1,830 shares worth more than $100,046.10. During the last year, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 700 shares worth more than $38,934.00. The most recent insider tranaction occured on November, 4th when SVP Phil M Holzer sold 700 shares worth more than $38,934.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.
Information on this page was last updated on 11/4/2024.

Samit Hirawat Insider Trading History at Bristol-Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/1/2024	Buy	1,830	$54.67	$100,046.10	62,109

Samit Hirawat Buying and Selling Activity at Bristol-Myers Squibb

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $57.33

$56.08

$57.33

50 Day Range

MA: $56.27

$51.92

$59.94

2 Week Range

Now: $57.33

$39.35

$61.08

Volume

45,935,973 shs

Average Volume

14,176,141 shs

Market Capitalization

$116.28 billion

P/E Ratio

N/A

Dividend Yield

4.30%

Beta

0.45

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Samit Hirawat Biography and Net Worth

What is Samit Hirawat's net worth?

How old is Samit Hirawat?

What is Samit Hirawat's salary?

How do I contact Samit Hirawat?

Has Samit Hirawat been buying or selling shares of Bristol-Myers Squibb?

Who are Bristol-Myers Squibb's active insiders?

Are insiders buying or selling shares of Bristol-Myers Squibb?